EcoDrugPlus

Solute Carrier Family 18 Member A2

Ensembl ID : ENSPLOG00000022197
Gene Symbol: SLC18A2
4 Cross references
223 Possible Orthologues:

Solute Carrier Family 22 Member 11

Ensembl ID : ENSPLOG00000013467
Gene Symbol: SLC22A11
2 Cross references
885 Possible Orthologues:

Solute Carrier Family 22 Member 12

Ensembl ID : ENSPLOG00000013797
Gene Symbol: SLC22A12
4 Cross references
470 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSPLOG00000008482
Gene Symbol: SLC22A6
2 Cross references
490 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSPLOG00000001064
Gene Symbol: SLC29A1
4 Cross references
284 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSPLOG00000020605
Gene Symbol: SLC5A1
2 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSPLOG00000007590
Gene Symbol: SLC5A2
4 Cross references
197 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSPLOG00000001048
Gene Symbol: SLC6A1
4 Cross references
276 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSPLOG00000007333
Gene Symbol: SLC6A2
4 Cross references
202 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSPLOG00000003913
Gene Symbol: SLC6A3
2 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSPLOG00000006083
Gene Symbol: SLC6A4
4 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSPLOG00000012002
Gene Symbol: SLC6A9
2 Cross references
207 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).